PTPRC and neoplasm: To our surprise, the application of JDB153 plus PD‐1 Ab significantly increased the proportion of CD45+ tumor‐infiltrating cells composed of CD4+ and CD8+ cells compared with the group of monotherapy or vehicle treatment (Figure 5A,B).